367 related articles for article (PubMed ID: 32470857)
1. Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS.
Vermersch P; Oh J; Cascione M; Oreja-Guevara C; Gobbi C; Travis LH; Myhr KM; Coyle PK
Mult Scler Relat Disord; 2020 Aug; 43():102158. PubMed ID: 32470857
[TBL] [Abstract][Full Text] [Related]
2. Teriflunomide for multiple sclerosis.
He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
[TBL] [Abstract][Full Text] [Related]
3. Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year.
Johnson KM; Zhou H; Lin F; Ko JJ; Herrera V
J Manag Care Spec Pharm; 2017 Aug; 23(8):844-852. PubMed ID: 28737986
[TBL] [Abstract][Full Text] [Related]
4. Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice.
Coyle PK; Khatri B; Edwards KR; Meca-Lallana JE; Cavalier S; Rufi P; Benamor M; Thangavelu K; Robinson M; Gold R;
Mult Scler Relat Disord; 2018 Nov; 26():211-218. PubMed ID: 30273841
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety of switching to teriflunomide in older patients with relapsing multiple sclerosis: A real-world retrospective multicenter analysis.
Berkovich R; Negroski D; Wynn D; Sellers D; Bzdek KG; Lublin AL; Rawlings AM; Quach C; Wells DP; Dumlao M; Bora A; Ranno AE; Luo KL; Chavin J; Hua LH; Becker D
Mult Scler Relat Disord; 2023 Feb; 70():104472. PubMed ID: 36566698
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
Ontaneda D; Nicholas J; Carraro M; Zhou J; Hou Q; Babb J; Riester K; Mendoza JP; Livingston T; Jhaveri M
Mult Scler Relat Disord; 2019 Jan; 27():101-111. PubMed ID: 30368221
[TBL] [Abstract][Full Text] [Related]
7. Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis.
Comi G; Freedman MS; Meca-Lallana JE; Vermersch P; Kim BJ; Parajeles A; Edwards KR; Gold R; Korideck H; Chavin J; Poole EM; Coyle PK
BMC Neurol; 2020 Oct; 20(1):364. PubMed ID: 33023488
[TBL] [Abstract][Full Text] [Related]
8. Patient-reported outcomes in relapsing forms of MS: Real-world, global treatment experience with teriflunomide from the Teri-PRO study.
Coyle PK; Khatri B; Edwards KR; Meca-Lallana JE; Cavalier S; Rufi P; Benamor M; Brette S; Robinson M; Gold R;
Mult Scler Relat Disord; 2017 Oct; 17():107-115. PubMed ID: 29055438
[TBL] [Abstract][Full Text] [Related]
9. Oral disease-modifying therapies for relapsing-remitting multiple sclerosis.
Thomas RH; Wakefield RA
Am J Health Syst Pharm; 2015 Jan; 72(1):25-38. PubMed ID: 25511835
[TBL] [Abstract][Full Text] [Related]
10. The Patient and Clinician Assessment of Gastrointestinal (GI) Related Adverse Events Associated with Oral Disease-Modifying Therapies in Multiple Sclerosis: A Qualitative Study.
Jivraj F; Kang S; Reedie S; Kapadia S; Strzok S; Elliott E; Cano S; Rock M
Adv Ther; 2022 Nov; 39(11):5072-5086. PubMed ID: 36053450
[TBL] [Abstract][Full Text] [Related]
11. Impact of diagnosis and early treatment on the course of multiple sclerosis.
Noyes K; Weinstock-Guttman B
Am J Manag Care; 2013 Nov; 19(17 Suppl):s321-31. PubMed ID: 24494633
[TBL] [Abstract][Full Text] [Related]
12. Oral agents in multiple sclerosis.
Lorefice L; Fenu G; Frau J; Coghe GC; Marrosu MG; Cocco E
Antiinflamm Antiallergy Agents Med Chem; 2015; 14(1):15-25. PubMed ID: 25924620
[TBL] [Abstract][Full Text] [Related]
13. An updated review of teriflunomide's use in multiple sclerosis.
Miller AE
Neurodegener Dis Manag; 2021 Oct; 11(5):387-409. PubMed ID: 34486382
[TBL] [Abstract][Full Text] [Related]
14. Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry.
Papp V; Buron MD; Siersma V; Rasmussen PV; Illes Z; Kant M; Hilt C; Mezei Z; Roshanisefat H; Sejbæk T; Weglewski A; van Wingerden J; Geertsen SS; Bramow S; Sellebjerg F; Magyari M
PLoS One; 2021; 16(5):e0250820. PubMed ID: 34003862
[TBL] [Abstract][Full Text] [Related]
15. Quality of life among injectable and oral disease-modifying therapy users in the Pacific Northwest Multiple Sclerosis Registry.
Stuchiner T; Lucas L; Baraban E; Spinelli KJ; Chen C; Smith A; Hashemi L; Cohan S
BMC Neurol; 2020 Dec; 20(1):439. PubMed ID: 33272224
[TBL] [Abstract][Full Text] [Related]
16. Teriflunomide for the treatment of relapsing multiple sclerosis: a review of clinical data.
Brunetti L; Wagner ML; Maroney M; Ryan M
Ann Pharmacother; 2013 Sep; 47(9):1153-60. PubMed ID: 24259730
[TBL] [Abstract][Full Text] [Related]
17. Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis.
Neuberger EE; Abbass IM; Jones E; Engmann NJ
Neurol Ther; 2021 Jun; 10(1):183-196. PubMed ID: 33244713
[TBL] [Abstract][Full Text] [Related]
18. Teriflunomide Concentrations in Cerebrospinal Fluid and Plasma in Patients with Multiple Sclerosis: A Pharmacokinetic Study.
Lycke J; Farman H; Nordin A
CNS Drugs; 2023 Feb; 37(2):181-188. PubMed ID: 36729276
[TBL] [Abstract][Full Text] [Related]
19. A retrospective claims analysis: Compliance and discontinuation rates among Canadian patients with multiple sclerosis treated with disease-modifying therapies.
Duquette P; Yeung M; Mouallif S; Nakhaipour HR; Haddad P; Schecter R
PLoS One; 2019; 14(1):e0210417. PubMed ID: 30640935
[TBL] [Abstract][Full Text] [Related]
20. Real world comparison of teriflunomide and dimethyl fumarate in naïve relapsing multiple sclerosis patients: Evidence from the Italian MS register.
Zanghì A; Avolio C; Amato MP; Filippi M; Trojano M; Patti F; Amico E;
Mult Scler Relat Disord; 2022 Feb; 58():103489. PubMed ID: 35032879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
